London, UK – Isomorphic Labs, the pioneering AI-driven drug discovery company spun out of Google DeepMind in 2021, is in advanced negotiations to secure over $2 billion in a new funding round. The Investment is being led by Thrive Capital, with participation expected from its parent company, Alphabet.
The substantial capital injection is poised to be one of the largest funding rounds in the AI制药 (AI pharmaceutical) sector to date. Isomorphic Labs plans to deploy the funds to accelerate the development of its proprietary AI drug design platform and fuel its international expansion.
Under the leadership of DeepMind CEO and Nobel Laureate Demis Hassabis, Isomorphic Labs is at the forefront of APPlying cutting-edge Artificial Intelligence to revolutionize drug research and development. The company's mission is to significantly accelerate the discovery process and reduce the high costs associated with bringing new medicines to patients.
This strategic Fundraising effort follows a series of major partnerships with global phArmaceutical giants, including Eli Lilly, Novartis, and Johnson & Johnson. These collaborations validate the company's Technology and its potential to unlock new therapeutic possibilities, particularly for historically "undruggable" targets.
The move marks another significant step in Alphabet's long-term strategy of transforming its most ambitious research projects into independent, commercially viable businesses.
Key Takeaways:
Funding: Isomorphic Labs is raising over $2 billion, led by Thrive Capital with participation from Alphabet.
Purpose: Funds will be used to enhance its AI drug design engine and support global business growth.
Context: The company has established major Partnerships with Eli Lilly, Novartis, and Johnson & Johnson.
Leadership: The company is led by Demis Hassabis, CEO of Google DeepMind.
Comments & Questions (0)
No comments yet
Be the first to comment!